282 related articles for article (PubMed ID: 16612649)
1. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
2. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
3. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
4. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
[TBL] [Abstract][Full Text] [Related]
5. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
6. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
7. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
9. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate.
Assaraf YG; Molina A; Schimke RT
J Biol Chem; 1989 Nov; 264(31):18326-34. PubMed ID: 2572592
[TBL] [Abstract][Full Text] [Related]
10. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
Chen ZS; Robey RW; Belinsky MG; Shchaveleva I; Ren XQ; Sugimoto Y; Ross DD; Bates SE; Kruh GD
Cancer Res; 2003 Jul; 63(14):4048-54. PubMed ID: 12874005
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine.
Assaraf YG; Slotky JI
J Biol Chem; 1993 Feb; 268(6):4556-66. PubMed ID: 8440739
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
13. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
14. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
Sharma RC; Assaraf YG; Schimke RT
Cancer Res; 1991 Jun; 51(11):2949-59. PubMed ID: 1674447
[TBL] [Abstract][Full Text] [Related]
15. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.
Fry DW; Besserer JA
Cancer Res; 1988 Dec; 48(24 Pt 1):6986-91. PubMed ID: 2973370
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
17. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
[TBL] [Abstract][Full Text] [Related]
18. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
20. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
